Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Metabolically armed tumor infiltrating lymphocytes cell therapy - Leman Biotech

Next Previous
Drug Profile

Metabolically armed tumor infiltrating lymphocytes cell therapy - Leman Biotech

Alternative Names: Meta10-TIL; Metabolically Armed TIL cells

Latest Information Update: 22 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Leman Biotech
  • Class Antineoplastics; Immunotherapies; Tumour infiltrating lymphocyte therapies
  • Mechanism of Action Immunologic cytotoxicity; Lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase 0 Solid tumours

Most Recent Events

  • 10 Jan 2026 Phase-0 for Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) (NCT07349160)
  • 06 Aug 2025 Preclinical trials in Solid tumours in China (IV) before August 2025 (Leman Biotech pipeline, August 2025)
  • 06 Aug 2025 Leman Biotech plans a phase 0 (Early phase I) trial for Solid tumours (Late-stage disease, Second-line therapy or greater, Metastatic disease, Recurrent) in China (IV) in August 2025 (NCT07106814)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top